New drug aims to cool artery inflammation and prevent heart attacks

NCT ID NCT07448038

Recruiting now Disease control Sponsor: Genentech, Inc. Source: ClinicalTrials.gov ↗

First seen Mar 11, 2026 · Last updated May 05, 2026 · Updated 7 times

Summary

This study tests an experimental drug called selnoflast in 162 people with atherosclerosis (hardened arteries) who are at high risk for heart attacks or strokes. The goal is to see if selnoflast can reduce inflammation in the arteries better than a placebo, when added to standard treatments. Participants will take the drug or placebo for 12 weeks, and doctors will measure inflammation using a special PET scan.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATHEROSCLEROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Alliance Clinical West Hills (Focus Clinical Research)
RECRUITING

West Hills, California, 91307, United States
Asha Clinical Research-Munster,Llc
RECRUITING

Hammond, Indiana, 46324, United States
Cardiovascular Research Foundation of Southern California
RECRUITING

Beverly Hills, California, 90210, United States
Eastside Research Associates, LLC dba Era Health Research
RECRUITING

Redmond, Washington, 98036, United States
Preferred Primary Care Physicians, Inc
RECRUITING

Pittsburgh, Pennsylvania, 15243, United States

Conditions

Explore the condition pages connected to this study.

ATHEROSCLEROSIS